» Articles » PMID: 10973841

Evidence of Improving Prognosis in Heart Failure: Trends in Case Fatality in 66 547 Patients Hospitalized Between 1986 and 1995

Overview
Journal Circulation
Date 2000 Sep 7
PMID 10973841
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Contemporary survival in unselected patients with heart failure and the population impact of newer therapies have not been widely studied. Therefore, we have documented case-fatality rates (CFRs) over a recent 10-year period.

Methods And Results: In Scotland, all hospitalizations and deaths are captured on a single database. We have studied case fatality in all patients admitted with a principal diagnosis of heart failure from 1986 to 1995. A total of 66 547 patients (47% male) were studied. Median age was 72 years in men and 78 years in women. Crude CFRs at 30 days and at 1, 5, and 10 years were 19.9%, 44.5%, 76.5%, and 87.6%, respectively. Median survival was 1.47 years in men and 1.39 years in women (2.47 and 2. 36 years, respectively, in those surviving 30 days). Age had a powerful effect on survival, and sex, comorbidity, and deprivation had modest effects. One-year CF was 24.2% in those aged <55 years and 58.1% in those aged >84 years. After adjustment, 30-day CFRs fell between 1986 and 1995, by 26% (95% CI 15 to 35, P<0.0001) in men and 17% (95% CI 6 to 26, P<0.0001) in women. Longer term CFRs fell by 18% (95% CI 13 to 24, P<0.0001) in men and 15% (95% CI 10 to 20, P<0.0001) in women. Median survival increased from 1.23 to 1. 64 years.

Conclusions: Heart failure CF is much higher in the general population than in clinical trials, especially in the elderly. Although survival has increased significantly over the last decade, there is still much room for improvement.

Citing Articles

Temporal Trends in Clinical Characteristics and Outcomes for Peripartum Cardiomyopathy: The Nationwide Multicenter Registry Over 20 Years.

Bak M, Youn J, Bae D, Lee J, Lee S, Cho D J Am Heart Assoc. 2024; 13(13):e034055.

PMID: 38904229 PMC: 11255681. DOI: 10.1161/JAHA.123.034055.


Heart failure in Nigeria: protocol for a systematic review and meta-analysis.

Ogah O, Kushimo O, Adebiyi A, Onyema C, Uchenna O, Adebayo B Afr Health Sci. 2024; 23(2):530-536.

PMID: 38223635 PMC: 10782286. DOI: 10.4314/ahs.v23i2.61.


The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020.

Mayer O, Bruthans J, Bilkova S, Seidlerova J, Jirak J, Filipovsky J Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022; 166(3):312-321.

PMID: 35444330 DOI: 10.5507/bp.2022.020.


Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).

Narkar A, Willard J, Blinova K Int J Mol Sci. 2022; 23(6).

PMID: 35328619 PMC: 8953833. DOI: 10.3390/ijms23063199.


Predictors of Exercise Capacity in Dilated Cardiomyopathy with Focus on Pulmonary Venous Flow Recorded with Transesophageal Eco-Doppler.

Caiati C, Argentiero A, Forleo C, Favale S, Lepera M J Clin Med. 2021; 10(24).

PMID: 34945249 PMC: 8706207. DOI: 10.3390/jcm10245954.